Review Article | Published:

The lung microenvironment: an important regulator of tumour growth and metastasis

Nature Reviews Cancervolume 19pages931 (2019) | Download Citation

Abstract

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Major advances in the identification of key mutational alterations have led to the development of molecularly targeted therapies, whose efficacy has been limited by emergence of resistance mechanisms. US Food and Drug Administration (FDA)-approved therapies targeting angiogenesis and more recently immune checkpoints have reinvigorated enthusiasm in elucidating the prognostic and pathophysiological roles of the tumour microenvironment in lung cancer. In this Review, we highlight recent advances and emerging concepts for how the tumour-reprogrammed lung microenvironment promotes both primary lung tumours and lung metastasis from extrapulmonary neoplasms by contributing to inflammation, angiogenesis, immune modulation and response to therapies. We also discuss the potential of understanding tumour microenvironmental processes to identify biomarkers of clinical utility and to develop novel targeted therapies against lung cancer.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

CCCExplorer: https://www.synapse.org/#!Synapse:syn10845895

NSCLC radiomics–genomics: https://wiki.cancerimagingarchive.net/display/Public/NSCLC-Radiomics-Genomics

References

  1. 1.

    Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 68, 7–30 (2018).

  2. 2.

    Herbst, R. S., Morgensztern, D. & Boshoff, C. The biology and management of non-small cell lung cancer. Nature 553, 446–454 (2018). This review highlights recent progress in lung cancer biology and therapeutic strategies that are impacting outcomes for patients with advanced-stage NSCLC.

  3. 3.

    Chen, Z., Fillmore, C. M., Hammerman, P. S., Kim, C. F. & Wong, K. K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat. Rev. Cancer 14, 535–546 (2014).

  4. 4.

    Mayekar, M. K. & Bivona, T. G. Current landscape of targeted therapy in lung cancer. Clin. Pharmacol. Ther. 102, 757–764 (2017).

  5. 5.

    Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).

  6. 6.

    Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309–322 (2012). This review highlights the TME as a key hallmark of carcinogenesis.

  7. 7.

    Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437 (2013).

  8. 8.

    Peinado, H. et al. Pre-metastatic niches: organ-specific homes for metastases. Nat. Rev. Cancer 17, 302–317 (2017). This is a comprehensive review on the pre-metastatic niche in cancer.

  9. 9.

    Houghton, A. M. Mechanistic links between COPD and lung cancer. Nat. Rev. Cancer 13, 233–245 (2013).

  10. 10.

    Banat, G. A. et al. Immune and inflammatory cell composition of human lung cancer stroma. PLOS ONE 10, e0139073 (2015).

  11. 11.

    Kargl, J. et al. Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat. Commun. 8, 14381 (2017).

  12. 12.

    Bremnes, R. M. et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J. Thorac Oncol. 6, 209–217 (2011).

  13. 13.

    Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582–598 (2016).

  14. 14.

    Wang, L. et al. Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3 signaling pathway. Oncotarget 8, 76116–76128 (2017).

  15. 15.

    Chen, W. J. et al. Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat. Commun. 5, 3472 (2014).

  16. 16.

    Navab, R. et al. Integrin α11β1 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer. Oncogene 35, 1899–1908 (2016).

  17. 17.

    Zhu, C. Q. et al. Integrin alpha 11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells. Proc. Natl Acad. Sci. USA 104, 11754–11759 (2007).

  18. 18.

    Chaudhri, V. K. et al. Metabolic alterations in lung cancer-associated fibroblasts correlated with increased glycolytic metabolism of the tumor. Mol. Cancer Res. 11, 579–592 (2013).

  19. 19.

    Nazareth, M. R. et al. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J. Immunol. 178, 5552–5562 (2007).

  20. 20.

    Lakins, M. A., Ghorani, E., Munir, H., Martins, C. P. & Shields, J. D. Cancer-associated fibroblasts induce antigen-specific deletion of CD8. Nat. Commun. 9, 948 (2018). References 19 and 20 show that CAFs modulate immune responses in the TME, as they express PDL1 to blunt activation of T cells and cross-present antigens to eliminate antigen-specific CD8 + T cells via PDL2 and FASL.

  21. 21.

    Kanzaki, R. et al. Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy. Sci. Rep. 7, 10613 (2017).

  22. 22.

    Ye, X. et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29, 5254–5264 (2010).

  23. 23.

    Lu, P., Weaver, V. M. & Werb, Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 196, 395–406 (2012).

  24. 24.

    Stawowczyk, M. et al. Matrix metalloproteinase 14 promotes lung cancer by cleavage of heparin-binding EGF-like growth factor. Neoplasia 19, 55–64 (2017).

  25. 25.

    Stevens, L. E. et al. Extracellular matrix receptor expression in subtypes of lung adenocarcinoma potentiates outgrowth of micrometastases. Cancer Res. 77, 1905–1917 (2017).

  26. 26.

    Marcus, A. I. & Zhou, W. LKB1 regulated pathways in lung cancer invasion and metastasis. J. Thorac Oncol. 5, 1883–1886 (2010).

  27. 27.

    Gao, Y. et al. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc. Natl Acad. Sci. USA 107, 18892–18897 (2010).

  28. 28.

    Salmon, H. et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J. Clin. Invest. 122, 899–910 (2012).

  29. 29.

    Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).

  30. 30.

    Dimitrova, N. et al. Stromal expression of miR-143/145 promotes neoangiogenesis in lung cancer development. Cancer Discov. 6, 188–201 (2016).

  31. 31.

    Xie, M., Liu, M. & He, C. S. SIRT1 regulates endothelial Notch signaling in lung cancer. PLOS ONE 7, e45331 (2012).

  32. 32.

    Pezzella, F. et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am. J. Pathol. 151, 1417–1423 (1997).

  33. 33.

    McClelland, M. R. et al. Diversity of the angiogenic phenotype in non-small cell lung cancer. Am. J. Respir. Cell. Mol. Biol. 36, 343–350 (2007).

  34. 34.

    Fridman, W. H., Zitvogel, L., Sautès-Fridman, C. & Kroemer, G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717–734 (2017).

  35. 35.

    Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014–1022 (2013).

  36. 36.

    Lavin, Y. et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell 169, 750–765 (2017). This is the first study to perform multiscale immune profiling using CyTOF and single-cell sequencing in patients with early-stage lung cancer.

  37. 37.

    Durrans, A. et al. Identification of reprogrammed myeloid cell transcriptomes in NSCLC. PLOS ONE 10, e0129123 (2015). This is the first study to sort individual myeloid cell subsets from tumour tissue and matched adjacent normal tissue from freshly harvested early-stage lung cancer specimens to identify tumour reprogrammed, differentially regulated genes.

  38. 38.

    Veglia, F., Perego, M. & Gabrilovich, D. Myeloid-derived suppressor cells coming of age. Nat. Immunol. 19, 108–119 (2018).

  39. 39.

    Engblom, C., Pfirschke, C. & Pittet, M. J. The role of myeloid cells in cancer therapies. Nat. Rev. Cancer 16, 447–462 (2016).

  40. 40.

    Schmid, M. C. & Varner, J. A. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J. Oncol. 2010, 201026 (2010).

  41. 41.

    Choi, H. et al. Transcriptome analysis of individual stromal cell populations identifies stroma-tumor crosstalk in mouse lung cancer model. Cell Rep. 10, 1187–1201 (2015). This study interrogates the complex tumour–stroma crosstalk in a mutant KRAS-driven lung cancer mouse model, which led to the development of the computational software CCCExplorer, which assesses cell–cell communication pathways from multicellular genomic data sets.

  42. 42.

    Kastenmüller, W., Kastenmüller, K., Kurts, C. & Seder, R. A. Dendritic cell-targeted vaccines—hope or hype? Nat. Rev. Immunol. 14, 705–711 (2014).

  43. 43.

    Schneider, T. et al. Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3. J. Thorac Oncol. 6, 1162–1168 (2011).

  44. 44.

    Dumitriu, I. E., Dunbar, D. R., Howie, S. E., Sethi, T. & Gregory, C. D. Human dendritic cells produce TGF-β1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 182, 2795–2807 (2009).

  45. 45.

    Yang, S. C. et al. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 66, 3205–3213 (2006).

  46. 46.

    Lee, J. M. et al. Phase I trial of intratumoral injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8+ T-cell infiltration. Clin. Cancer Res. 23, 4556–4568 (2017).

  47. 47.

    Saxena, M. & Bhardwaj, N. Re-emergence of dendritic cell vaccines for cancer treatment. Trends Cancer 4, 119–137 (2018).

  48. 48.

    Gabrilovich, D. I. Myeloid-derived suppressor cells. Cancer Immunol. Res. 5, 3–8 (2017). This is a comprehensive review on MDSCs in cancer.

  49. 49.

    Coffelt, S. B., Wellenstein, M. D. & de Visser, K. E. Neutrophils in cancer: neutral no more. Nat. Rev. Cancer 16, 431–446 (2016).

  50. 50.

    Condamine, T. et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci. Immunol. 1, aaf8943 (2016).

  51. 51.

    Almatroodi, S. A., McDonald, C. F., Darby, I. A. & Pouniotis, D. S. Characterization of M1/M2 tumour-associated macrophages (TAMs) and Th1/Th2 cytokine profiles in patients with NSCLC. Cancer Microenviron. 9, 1–11 (2016).

  52. 52.

    Ohri, C. M., Shikotra, A., Green, R. H., Waller, D. A. & Bradding, P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur. Respir. J. 33, 118–126 (2009).

  53. 53.

    Ginhoux, F., Schultze, J. L., Murray, P. J., Ochando, J. & Biswas, S. K. New insights into the multidimensional concept of macrophage ontogeny, activation and function. Nat. Immunol. 17, 34–40 (2016).

  54. 54.

    Conway, E. M. et al. Macrophages, inflammation, and lung cancer. Am. J. Respir. Crit. Care Med. 193, 116–130 (2016).

  55. 55.

    Wang, D. H. et al. Progression of EGFR-mutant lung adenocarcinoma is driven by alveolar macrophages. Clin. Cancer Res. 23, 778–788 (2017).

  56. 56.

    Fritz, J. M. et al. Depletion of tumor-associated macrophages slows the growth of chemically induced mouse lung adenocarcinomas. Front. Immunol. 5, 587 (2014).

  57. 57.

    Cannarile, M. A. et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J. Immunother. Cancer 5, 53 (2017).

  58. 58.

    Kumar, V. et al. Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell 32, 654–668 (2017). This study provides a new mechanism of resistance to CSF1R inhibitors and suggests the implementation of a rationally designed combination therapy.

  59. 59.

    Sionov, R. V., Fridlender, Z. G. & Granot, Z. The multifaceted roles neutrophils play in the tumor microenvironment. Cancer Microenviron. 8, 125–158 (2015).

  60. 60.

    Mantovani, A., Cassatella, M. A., Costantini, C. & Jaillon, S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 11, 519–531 (2011). This is a comprehensive review describing how neutrophils regulate immunity.

  61. 61.

    Singhal, S. et al. Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer. Cancer Cell 30, 120–135 (2016). This study shows that APC-like ‘hybrid neutrophils’ cross-present antigens and trigger antitumour T cell responses in human lung cancer.

  62. 62.

    McLoed, A. G. et al. Neutrophil-derived IL-1β impairs the efficacy of NF-κB inhibitors against lung cancer. Cell Rep. 16, 120–132 (2016).

  63. 63.

    Vikis, H. G. et al. Neutrophils are required for 3-methylcholanthrene-initiated, butylated hydroxytoluene-promoted lung carcinogenesis. Mol. Carcinog. 51, 993–1002 (2012).

  64. 64.

    Engblom, C. et al. Osteoblasts remotely supply lung tumors with cancer-promoting SiglecF. Science 358, eaal5081 (2017). This study highlights a new mechanism by which primary lung tumours mediate crosstalk with the bone marrow to generate a new class of tumour-promoting neutrophils.

  65. 65.

    Spits, H. & Cupedo, T. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu. Rev. Immunol. 30, 647–675 (2012).

  66. 66.

    Cerwenka, A. & Lanier, L. L. Natural killers join the fight against cancer. Science 359, 1460–1461 (2018).

  67. 67.

    Carrega, P. & Ferlazzo, G. Natural killers are made not born: how to exploit NK cells in lung malignancies. Front. Immunol. 8, 277 (2017).

  68. 68.

    Bruno, A. et al. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia 15, 133–142 (2013).

  69. 69.

    Vacca, P. et al. NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation. Eur. J. Immunol. 43, 550–561 (2013).

  70. 70.

    Markowitz, G. J. et al. Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival. JCI Insight 3, e96836 (2018). This study demonstrates the efficacy of anti-PD1 monotherapy and its impact on the immune microenvironment in an orthotopic mutant KRAS-driven model of NSCLC.

  71. 71.

    Sharma, S. et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer. Cancer Res. 65, 5211–5220 (2005). This study shows that CAFs express COX2, which promotes secretion of PGE 2 to induce immunosuppressive FOXP3 + T reg cells.

  72. 72.

    Granville, C. A. et al. A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis. PLOS ONE 4, e5061 (2009).

  73. 73.

    Ganesan, A. P. et al. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J. Immunol. 191, 2009–2017 (2013).

  74. 74.

    Marshall, E. A. et al. Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis. Mol. Cancer 15, 67 (2016).

  75. 75.

    Petersen, R. P. et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107, 2866–2872 (2006).

  76. 76.

    Reppert, S. et al. A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer. Nat. Commun. 2, 600 (2011).

  77. 77.

    Dunn, G. P., Old, L. J. & Schreiber, R. D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329–360 (2004).

  78. 78.

    Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486–499 (2015).

  79. 79.

    Thommen, D. S. et al. Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. Cancer Immunol. Res. 3, 1344–1355 (2015).

  80. 80.

    Kamphorst, A. O. et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc. Natl Acad. Sci. USA 114, 4993–4998 (2017).

  81. 81.

    Germain, C. et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am. J. Respir. Crit. Care Med. 189, 832–844 (2014).

  82. 82.

    Bruno, T. C. et al. Antigen-presenting intratumoral B cells affect CD4. Cancer Immunol. Res. 5, 898–907 (2017).

  83. 83.

    Turley, S. J., Cremasco, V. & Astarita, J. L. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat. Rev. Immunol. 15, 669–682 (2015).

  84. 84.

    Busch, S. E. et al. Lung cancer subtypes generate unique immune responses. J. Immunol. 197, 4493–4503 (2016).

  85. 85.

    Spranger, S. & Gajewski, T. F. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat. Rev. Cancer 18, 139–147 (2018). This is a comprehensive review on the impact of cancer cell-intrinsic pathways on immunomodulation.

  86. 86.

    Liu, C. Y. et al. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 136, 35–45 (2010).

  87. 87.

    Feng, P. H. et al. CD14+S100A9+ monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am. J. Respir. Crit. Care Med. 186, 1025–1036 (2012).

  88. 88.

    Smith, C. et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2, 722–735 (2012).

  89. 89.

    Schafer, C. C. et al. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment. Oncotarget 7, 75407–75424 (2016).

  90. 90.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02752074?term=NCT02752074&rank=1 (2018).

  91. 91.

    Woodard, P. K., Dehdashti, F. & Putman, C. E. Radiologic diagnosis of extrathoracic metastases to the lung. Oncol. (Williston Park) 12, 431–438; discussion 441–442 (1998).

  92. 92.

    Francia, G., Cruz-Munoz, W., Man, S., Xu, P. & Kerbel, R. S. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat. Rev. Cancer 11, 135–141 (2011).

  93. 93.

    Liu, Y. & Cao, X. Characteristics and significance of the pre-metastatic niche. Cancer Cell 30, 668–681 (2016).

  94. 94.

    Zhou, W. et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 25, 501–515 (2014).

  95. 95.

    Qian, B. Z. et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475, 222–225 (2011).

  96. 96.

    Erler, J. T. et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15, 35–44 (2009). This study demonstrates that hypoxia in the primary breast tumour triggers expression of lysyl oxidase, which systemically crosslinks collagen in the lungs, to increase adhesion of myeloid cells, generating niches that support metastatic colonization.

  97. 97.

    Liu, Y. et al. Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating alveolar epithelial TLR3 to recruit neutrophils. Cancer Cell 30, 243–256 (2016).

  98. 98.

    Wculek, S. K. & Malanchi, I. Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature 528, 413–417 (2015).

  99. 99.

    Coffelt, S. B. et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522, 345–348 (2015).

  100. 100.

    El Rayes, T. et al. Lung inflammation promotes metastasis through neutrophil protease-mediated degradation of Tsp-1. Proc. Natl Acad. Sci. USA 112, 16000–16005 (2015).

  101. 101.

    Massara, M. et al. ACKR2 in hematopoietic precursors as a checkpoint of neutrophil release and anti-metastatic activity. Nat. Commun. 9, 676 (2018).

  102. 102.

    Chen, Q., Zhang, X. H. & Massagué, J. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 20, 538–549 (2011).

  103. 103.

    Malanchi, I. et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481, 85–89 (2012).

  104. 104.

    Oskarsson, T. et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat. Med. 17, 867–874 (2011). References 103 and 104 show that tumour cell–fibroblast crosstalk promotes metastasis.

  105. 105.

    Gao, D. et al. Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res. 15, 1384–1394 (2012). This study shows that reprogrammed myeloid cells express the proteoglycan versican to promote MET of DTCs in the lungs.

  106. 106.

    Del Pozo Martin, Y. et al. Mesenchymal cancer cell-stroma crosstalk promotes niche activation, epithelial reversion, and metastatic colonization. Cell Rep. 13, 2456–2469 (2015).

  107. 107.

    Gao, D. et al. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319, 195–198 (2008).

  108. 108.

    Minami, T. et al. The calcineurin-NFAT-angiopoietin-2 signaling axis in lung endothelium is critical for the establishment of lung metastases. Cell Rep. 4, 709–723 (2013).

  109. 109.

    López-Soto, A., Gonzalez, S., Smyth, M. J. & Galluzzi, L. Control of metastasis by NK cells. Cancer Cell 32, 135–154 (2017).

  110. 110.

    Carrega, P. et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56brightCD16- cells and display an impaired capability to kill tumor cells. Cancer 112, 863–875 (2008).

  111. 111.

    Blake, S. J. et al. Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Cancer Discov. 6, 446–459 (2016).

  112. 112.

    Sceneay, J. et al. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res. 72, 3906–3911 (2012).

  113. 113.

    Molgora, M. et al. IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity. Nature 551, 110–114 (2017).

  114. 114.

    Catena, R. et al. Bone marrow-derived gr1 + cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov. 3, 578–589 (2013). This study shows that metastatic incompetent tumours express the glycoprotein prosaposin to reprogramme myeloid cells in the lungs to express TSP1 to generate metastasis-suppressive niches. A peptide of five amino acids in length derived from prosaposin with TSP1-inducing activity has anti-metastatic activity in preclinical models.

  115. 115.

    Hanna, R. N. et al. Patrolling monocytes control tumor metastasis to the lung. Science 350, 985–990 (2015). This study shows that lung endothelial cells attract CX 3 CR1 + patrolling monocytes, which through expression of CCL3, CCL4 and CCL5 recruit cytotoxic NK cells to prevent metastasis to the lung in mice.

  116. 116.

    Murin, S., Pinkerton, K. E., Hubbard, N. E. & Erickson, K. The effect of cigarette smoke exposure on pulmonary metastatic disease in a murine model of metastatic breast cancer. Chest 125, 1467–1471 (2004).

  117. 117.

    Murin, S. & Inciardi, J. Cigarette smoking and the risk of pulmonary metastasis from breast cancer. Chest 119, 1635–1640 (2001).

  118. 118.

    Yan, L., Cai, Q. & Xu, Y. The ubiquitin-CXCR4 axis plays an important role in acute lung infection-enhanced lung tumor metastasis. Clin. Cancer Res. 19, 4706–4716 (2013).

  119. 119.

    Jiang, M. et al. Systemic inflammation promotes lung metastasis via E-selectin upregulation in mouse breast cancer model. Cancer Biol. Ther. 15, 789–796 (2014).

  120. 120.

    Stathopoulos, G. T. et al. Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol. Cancer Res. 6, 364–371 (2008).

  121. 121.

    Said, N., Sanchez-Carbayo, M., Smith, S. C. & Theodorescu, D. RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J. Clin. Invest. 122, 1503–1518 (2012).

  122. 122.

    Clever, D. et al. Oxygen sensing by T cells establishes an immunologically tolerant metastatic niche. Cell 166, 1117–1131 (2016).

  123. 123.

    Ghajar, C. M. Metastasis prevention by targeting the dormant niche. Nat. Rev. Cancer 15, 238–247 (2015).

  124. 124.

    Aguirre-Ghiso, J. A., Bragado, P. & Sosa, M. S. Metastasis awakening: targeting dormant cancer. Nat. Med. 19, 276–277 (2013).

  125. 125.

    Linde, N., Fluegen, G. & Aguirre-Ghiso, J. A. The relationship between dormant cancer cells and their microenvironment. Adv. Cancer Res. 132, 45–71 (2016).

  126. 126.

    Romero, I., Garrido, F. & Garcia-Lora, A. M. Metastases in immune-mediated dormancy: a new opportunity for targeting cancer. Cancer Res. 74, 6750–6757 (2014).

  127. 127.

    Wood, S. L., Pernemalm, M., Crosbie, P. A. & Whetton, A. D. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat. Rev. 40, 558–566 (2014).

  128. 128.

    Pitt, J. M. et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann. Oncol. 27, 1482–1492 (2016).

  129. 129.

    Pilotto, S. et al. Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a ‘hard days night’. Curr. Pharm. Des. 20, 3958–3972 (2014).

  130. 130.

    Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542–2550 (2006). This study is responsible for the FDA approval of bevacizumab for patients with advanced NSCLC.

  131. 131.

    Garon, E. B. et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384, 665–673 (2014). This study led to the approval of ramucirumab, a VEGFR2-targeting antibody in combination with docetaxel chemotherapy for the treatment of patients with metastatic NSCLC who have progressed on or after platinum-based chemotherapy.

  132. 132.

    Reck, M. et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 15, 143–155 (2014). This study led to the approval in the European Union of nintedanib in combination with docetaxel for the treatment of patients with advanced pretreated NSCLC.

  133. 133.

    Tabchi, S. & Blais, N. Antiangiogenesis for advanced non-small-cell lung cancer in the era of immunotherapy and personalized medicine. Front. Oncol. 7, 52 (2017).

  134. 134.

    Wang, D. & Dubois, R. N. Prostaglandins and cancer. Gut 55, 115–122 (2006).

  135. 135.

    Cuzick, J. et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann. Oncol. 26, 47–57 (2015).

  136. 136.

    Mc Menamin, Ú., Cardwell, C. R., Hughes, C. M. & Murray, L. M. Low-dose aspirin and survival from lung cancer: a population-based cohort study. BMC Cancer 15, 911 (2015).

  137. 137.

    Hochmuth, F., Jochem, M. & Schlattmann, P. Meta-analysis of aspirin use and risk of lung cancer shows notable results. Eur. J. Cancer Prev. 25, 259–268 (2016).

  138. 138.

    Edelman, M. J., Hodgson, L., Wang, X., Kratzke, R. A. & Vokes, E. E. Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer. J. Clin. Oncol. 30, 2019–2020; author reply 2020 (2012).

  139. 139.

    Edelman, M. J. et al. Phase III randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non-small-cell lung cancer with cyclooxygenase-2 overexpression: CALGB 30801 (Alliance). J. Clin. Oncol. 35, 2184–2192 (2017).

  140. 140.

    Solomon, D. H. et al. The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: a secondary analysis of the PRECISION trial. Am. J. Med. 130, 1415–1422 (2017).

  141. 141.

    Ridker, P. M. et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390, 1833–1842 (2017).

  142. 142.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03447769?term=NCT03447769&rank=1 (2018).

  143. 143.

    Zavala, V. A. & Kalergis, A. M. New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 145, 182–201 (2015).

  144. 144.

    Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).

  145. 145.

    Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015). References 144 and 145 are responsible for the approval of the PD1 antibody nivolumab.

  146. 146.

    Vokes, E. E. et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann. Oncol. 29, 959–965 (2018).

  147. 147.

    Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028 (2015). This study is responsible for the approval of the PD1 antibody pembrolizumab for previously treated patients with NSCLC (regardless of the tumour histology) whose tumours expressed PDL1.

  148. 148.

    Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540–1550 (2016).

  149. 149.

    Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016). This study reports on a randomized phase III trial, which led to the FDA approval of pembrolizumab for patients with advanced NSCLC expressing PDL1 in > 50% of tumour cells.

  150. 150.

    Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255–265 (2017).

  151. 151.

    Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377, 1919–1929 (2017). This study is responsible for the rapid breakthrough designation by the FDA of durvalumab for locally advanced, stage III NSCLC with no progression after chemoradiation.

  152. 152.

    Rimm, D. L. et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol. 3, 1051–1058 (2017).

  153. 153.

    Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205–214 (2015).

  154. 154.

    Patel, S. A. & Minn, A. J. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity 48, 417–433 (2018).

  155. 155.

    Zappasodi, R., Merghoub, T. & Wolchok, J. D. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell 33, 581–598 (2018). References 153, 154 and 155 discuss the functional roles and determinants of immune checkpoint blockade, immunotherapy combinations and biomarkers for treatment optimization.

  156. 156.

    Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078–2092 (2018). This paper reports on a double-blind phase III trial confirming that the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum drug results in significantly longer OS and PFS than chemotherapy alone irrespective of PDL1 levels in previously untreated metastatic non-squamous NSCLC without EGFR or ALK mutations.

  157. 157.

    Hellmann, M. D. et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 18, 31–41 (2017). This paper reports a phase I trial showing that in patients with high TMB (at least 10 mutations per megabase), nivolumab plus ipilimumab significantly improve PFS compared with chemotherapy irrespective of PDL1 levels.

  158. 158.

    Hellmann, M. D. et al. Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093–2104 (2018).

  159. 159.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02366143?term=NCT02366143&rank=1 (2018).

  160. 160.

    Ngwa, W. et al. Using immunotherapy to boost the abscopal effect. Nat. Rev. Cancer 18, 313–322 (2018).

  161. 161.

    Golden, E. B., Demaria, S., Schiff, P. B., Chachoua, A. & Formenti, S. C. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol. Res. 1, 365–372 (2013). This study is the first to demonstrate an abscopal response to radiation and ipilimumab in a patient with metastatic NSCLC.

  162. 162.

    Jones, P. A., Issa, J. P. & Baylin, S. Targeting the cancer epigenome for therapy. Nat. Rev. Genet. 17, 630–641 (2016).

  163. 163.

    Adeegbe, D. O. et al. Synergistic immunostimulatory effects and therapeutic benefit of combined histone deacetylase and bromodomain inhibition in non-small cell lung cancer. Cancer Discov. 7, 852–867 (2017).

  164. 164.

    Juergens, R. A. et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 1, 598–607 (2011).

  165. 165.

    Skoulidis, F. et al. Mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 8, 822–835 (2018).

  166. 166.

    Koyama, S. et al. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res. 76, 999–1008 (2016).

  167. 167.

    Forde, P. M. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl. J. Med. 378, 1976–1986 (2018).

  168. 168.

    Granot, Z. et al. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 20, 300–314 (2011). This study describes a metastasis-suppressive role for neutrophils.

  169. 169.

    Cox, T. R., Gartland, A. & Erler, J. T. Lysyl oxidase, a targetable secreted molecule involved in cancer metastasis. Cancer Res. 76, 188–192 (2016).

  170. 170.

    Labelle, M., Begum, S. & Hynes, R. O. Platelets guide the formation of early metastatic niches. Proc. Natl Acad. Sci. USA 111, E3053–E3061 (2014).

  171. 171.

    Bonapace, L. et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 515, 130–133 (2014).

  172. 172.

    Kurzrock, R. & Stewart, D. J. Exploring the benefit/risk associated with antiangiogenic agents for the treatment of non-small cell lung cancer patients. Clin. Cancer Res. 23, 1137–114 (2017).

  173. 173.

    Moserle, L., Jiménez-Valerio, G. & Casanovas, O. Antiangiogenic therapies: going beyond their limits. Cancer Discov. 4, 31–41 (2014).

  174. 174.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01532089?term=NCT01532089&rank=1 (2018).

  175. 175.

    Goldberg, S. B. et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin Cancer Res. 24, 1872–1880 (2018).

  176. 176.

    Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G. & Jain, R. K. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15, 325–340 (2018).

  177. 177.

    Khan, K. A. & Kerbel, R. S. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat. Rev. Clin. Oncol. 15, 310–324 (2018). References 176 and 177 discuss the rationale for combining antiangiogenic therapies with immunotherapy.

  178. 178.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02443324?term=NCT02443324&rank=1 (2018).

  179. 179.

    Berman, A. T. & Simone, C. B. Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation? Transl Lung Cancer Res. 5, 138–142 (2016).

  180. 180.

    Taunk, N. K. et al. Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer. Transl Lung Cancer Res. 6, 178–185 (2017).

  181. 181.

    Aberle, D. R. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395–409 (2011).

  182. 182.

    Ishihara, J. et al. Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. Sci. Transl Med. 9, eaan0401 (2017).

  183. 183.

    Lambrechts, D. et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat. Med. 24, 1277–1289 (2018).

  184. 184.

    Remark, R. et al. In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. Sci. Immunol. 1, aaf6925 (2016).

  185. 185.

    Lizotte, P. H. et al. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. JCI Insight 1, e89014 (2016).

  186. 186.

    Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938–945 (2015). This study demonstrates that deconvolution of bulk gene expression data can be used to estimate cellular compositions of human tumours.

  187. 187.

    Lambin, P. et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat. Rev. Clin. Oncol. 14, 749–762 (2017).

  188. 188.

    Entenberg, D. et al. A permanent window for the murine lung enables high-resolution imaging of cancer metastasis. Nat. Methods 15, 73–80 (2018).

  189. 189.

    Looney, M. R. et al. Stabilized imaging of immune surveillance in the mouse lung. Nat. Methods 8, 91–96 (2011). References 188 and 189 show real-time dynamic interactions in the lung microenvironment.

  190. 190.

    Cuccarese, M. F. et al. Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging. Nat. Commun. 8, 14293 (2017).

  191. 191.

    Politi, K. et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 20, 1496–1510 (2006).

  192. 192.

    DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4, 1064–1072 (2009).

  193. 193.

    Maddalo, D. et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 516, 423–427 (2014). References 191, 192 and 193 describe mouse models of lung cancer with prominent oncogenic drivers including mutant EGFR and KRAS and the EML–ALK4 translocation.

  194. 194.

    Koyama, S. et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun. 7, 0501 (2016).

  195. 195.

    Pfirschke, C. et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 44, 343–354 (2016).

  196. 196.

    Westcott, P. M. et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517, 489–492 (2015).

  197. 197.

    McFadden, D. G. et al. Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma. Proc. Natl Acad. Sci. USA 113, E6409–E6417 (2016). This study shows that oncogene-driven lung adenocarcinomas in GEMMs harbour few somatic mutations compared with human lung adenocarcinomas. By contrast, reference 70 shows that an orthotopic mutant KRAS-driven mouse model of NSCLC harbours a mutational burden comparable to non-smoker early-stage human NSCLC.

  198. 198.

    DuPage, M. et al. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 19, 72–85 (2011).

  199. 199.

    Li, H. Y. et al. The tumor microenvironment regulates sensitivity of murine lung tumors to PD-1/PD-L1 antibody blockade. Cancer Immunol. Res. 5, 767–777 (2017).

  200. 200.

    Aparicio, S., Hidalgo, M. & Kung, A. L. Examining the utility of patient-derived xenograft mouse models. Nat. Rev. Cancer 15, 311–316 (2015).

  201. 201.

    Morgan, K. M., Riedlinger, G. M., Rosenfeld, J., Ganesan, S. & Pine, S. R. Patient-derived xenograft models of non-small cell lung cancer and their potential utility in personalized medicine. Front. Oncol. 7, 2 (2017).

  202. 202.

    Zitvogel, L., Pitt, J. M., Daillère, R., Smyth, M. J. & Kroemer, G. Mouse models in oncoimmunology. Nat. Rev. Cancer 16, 759–773 (2016).

  203. 203.

    Ben-David, U. et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat. Genet. 49, 1567–1575 (2017).

  204. 204.

    Walsh, N. C. et al. Humanized mouse models of clinical disease. Annu. Rev. Pathol. 12, 187–215 (2017).

  205. 205.

    Karekla, E. et al. Ex vivo explant cultures of non-small cell lung carcinoma enable evaluation of primary tumor responses to anticancer therapy. Cancer Res. 2, 2029–2039 (2017).

  206. 206.

    Hassell, B. A. et al. Human organ chip models recapitulate orthotopic lung cancer growth, therapeutic responses, and tumor dormancy in vitro. Cell Rep. 21, 508–516 (2017).

  207. 207.

    Eisenblaetter, M. et al. Visualization of tumor-immune interaction - target-specific imaging of S100A8/A9 reveals pre-metastatic niche establishment. Theranostics 7, 2392–2401 (2017).

  208. 208.

    Shokeen, M. et al. Molecular imaging of very late antigen-4 (α4β1 integrin) in the premetastatic niche. J. Nucl. Med. 53, 779–786 (2012).

  209. 209.

    Kim, C. & Giaccone, G. Precision oncology in non-small-cell lung cancer: opportunities and challenges. Nat. Rev. Clin. Oncol. 15, 348–349 (2018).

  210. 210.

    Ostman, A. The tumor microenvironment controls drug sensitivity. Nat. Med. 18, 1332–1334 (2012).

  211. 211.

    Penet, M. F., Krishnamachary, B., Chen, Z., Jin, J. & Bhujwalla, Z. M. Molecular imaging of the tumor microenvironment for precision medicine and theranostics. Adv. Cancer Res. 124, 235–256 (2014).

  212. 212.

    Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).

  213. 213.

    Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812–830 (2018).

  214. 214.

    Dijkstra, K. K. et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell 174, 1586–1598 (2018).

  215. 215.

    Ito, M. et al. Prognostic impact of cancer-associated stromal cells in stage I lung adenocarcinoma patients. Chest 142, 151–158 (2012).

  216. 216.

    Navab, R. et al. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc. Natl Acad. Sci. USA 108, 7160–7165 (2011).

  217. 217.

    Gocheva, V. et al. Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival. Proc. Natl Acad. Sci. USA 114, E5625–E5634 (2017).

  218. 218.

    Lim, S. B., Tan, S. J., Lim, W. T. & Lim, C. T. An extracellular matrix-related prognostic and predictive indicator for early-stage non-small cell lung cancer. Nat. Commun. 8, 1734 (2017).

  219. 219.

    Brambilla, E. et al. Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer. J. Clin. Oncol. 34, 1223–1230 (2016).

  220. 220.

    Reynders, K. & De Ruysscher, D. Tumor infiltrating lymphocytes in lung cancer: a new prognostic parameter. J. Thorac Dis. 8, E833–E835 (2016).

  221. 221.

    Shimizu, K. et al. Tumor-infiltrating Foxp3 + regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J. Thorac Oncol. 5, 585–590 (2010).

  222. 222.

    Pagès, F. et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391, 2128–2139 (2018).

  223. 223.

    Donnem, T. et al. Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. Ann. Oncol. 27, 225–232 (2016). References 222 and 223 discuss the implementation of the immunoscore for predicting risk in colon cancer and strategies to apply a similar immunoscore in the clinic for lung cancer, respectively.

  224. 224.

    Paulsen, E. E. et al. Assessing PDL-1 and PD-1 in non-small cell lung cancer: a novel immunoscore approach. Clin. Lung Cancer 18, 220–233 (2017).

  225. 225.

    Remark, R. et al. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am. J. Respir. Crit. Care Med. 191, 377–390 (2015).

  226. 226.

    Rehman, J. A. et al. Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. Mod. Pathol. 30, 340–349 (2017).

  227. 227.

    Mansfield, A. S. et al. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann. Oncol. 27, 1953–1958 (2016).

  228. 228.

    Hirsch, F. R. et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J. Thorac Oncol. 12, 208–222 (2017).

  229. 229.

    Ratcliffe, M. J. et al. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer. Clin. Cancer Res. 23, 3585–3591 (2017).

  230. 230.

    Govindan, R. et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150, 1121–1134 (2012). This study uses genomic analysis of lung cancer to show that the average mutation frequency is more than tenfold higher in smokers than in non-smokers.

  231. 231.

    Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015). This study shows that higher TMB in patients with NSCLC is associated with improved objective response rates, durable clinical benefit and PFS.

  232. 232.

    Carbone, D. P. et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426 (2017).

  233. 233.

    Hellmann, M. D. et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell 33, 853–861 (2018). This study shows that TMB is predictive of clinical efficacy independent of PDL1 expression.

  234. 234.

    Messmer, M. N., Netherby, C. S., Banik, D. & Abrams, S. I. Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol. Immunother. 64, 1–13 (2015).

  235. 235.

    Jackute, J. et al. Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer. BMC Immunol. 19, 3 (2018).

  236. 236.

    Dieu-Nosjean, M. C. et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26, 4410–4417 (2008).

  237. 237.

    Goc, J. et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8 + T cells. Cancer Res. 74, 705–715 (2014).

  238. 238.

    Fucikova, J. et al. Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis. Cancer Res. 76, 1746–1756 (2016).

  239. 239.

    Stoll, G. et al. Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. Oncoimmunology 5, e1177692 (2016).

  240. 240.

    Ghajar, C. M. et al. The perivascular niche regulates breast tumour dormancy. Nat. Cell Biol. 15, 807–817 (2013).

  241. 241.

    Gao, H. et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 150, 764–779 (2012).

  242. 242.

    Gao, H. et al. Multi-organ site metastatic reactivation mediated by non-canonical discoidin domain receptor 1 signaling. Cell 166, 47–62 (2016).

  243. 243.

    Barkan, D. et al. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res. 68, 6241–6250 (2008).

  244. 244.

    Barkan, D. et al. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res. 70, 5706–5716 (2010).

  245. 245.

    De Cock, J. M. et al. Inflammation triggers Zeb1-dependent escape from tumor latency. Cancer Res. 76, 6778–6784 (2016).

  246. 246.

    Villano, J. L. et al. Incidence of brain metastasis at initial presentation of lung cancer. Neuro Oncol. 17, 122–128 (2015).

  247. 247.

    Ali, A., Goffin, J. R., Arnold, A. & Ellis, P. M. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr. Oncol. 20, e300–e306 (2013).

  248. 248.

    Seike, T. et al. Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis. Clin. Exp. Metastasis 28, 13–25 (2011).

  249. 249.

    Wang, L. et al. Astrocytes directly influence tumor cell invasion and metastasis in vivo. PLOS ONE 8, e80933 (2013).

  250. 250.

    Li, B. et al. Elevated PLGF contributes to small-cell lung cancer brain metastasis. Oncogene 32, 2952–2962 (2013).

  251. 251.

    Valiente, M. et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156, 1002–1016 (2014).

  252. 252.

    Nguyen, D. X. et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138, 51–62 (2009).

  253. 253.

    Tang, C. H., Tan, T. W., Fu, W. M. & Yang, R. S. Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis 29, 35–43 (2008).

  254. 254.

    Müller, P. et al. Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells. Cancer Immunol. Immunother. 65, 1–11 (2016).

  255. 255.

    Reticker-Flynn, N. E. & Bhatia, S. N. Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche. Cancer Discov. 5, 168–181 (2015).

  256. 256.

    Hogan, B. L. et al. Repair and regeneration of the respiratory system: complexity, plasticity, and mechanisms of lung stem cell function. Cell Stem Cell 15, 123–138 (2014).

  257. 257.

    Stevens, T. et al. Lung vascular cell heterogeneity: endothelium, smooth muscle, and fibroblasts. Proc. Am. Thorac Soc. 5, 783–791 (2008).

  258. 258.

    Ding, B. S. et al. Endothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization. Cell 147, 539–553 (2011).

  259. 259.

    Lee, J. H. et al. Lung stem cell differentiation in mice directed by endothelial cells via a BMP4-NFATc1-thrombospondin-1 axis. Cell 156, 440–455 (2014).

  260. 260.

    Morales-Nebreda, L., Misharin, A. V., Perlman, H. & Budinger, G. R. The heterogeneity of lung macrophages in the susceptibility to disease. Eur. Respir. Rev. 24, 505–509 (2015).

  261. 261.

    Takamura, S. Niches for the long-term maintenance of tissue-resident memory T cells. Front. Immunol. 9, 1214 (2018).

  262. 262.

    Chen, N. et al. KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma. Cancer Immunol. Immunother. 66, 1175–1187 (2017).

  263. 263.

    Coelho, M. A. et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity 47, 1083–1099 (2017). References 262 and 263 provide mechanistic insights into how activated KRAS upregulates PDL1.

  264. 264.

    Kortlever, R. M. et al. Myc cooperates with Ras by programming inflammation and immune suppression. Cell 171, 1301–1315 (2017).

  265. 265.

    Azuma, K. et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann. Oncol. 25, 1935–1940 (2014).

  266. 266.

    Akbay, E. A. et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 3, 1355–1363 (2013). References 265 and 266 show that mutant EGFR induces PDL1 expression to mediate immune escape in human and mouse lung tumours, respectively.

  267. 267.

    Ota, K. et al. Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer. Clin. Cancer Res. 21, 4014–4021 (2015). References 262 and 267 show that mutant KRAS and the EML–ALK4 oncoprotein induce PDL1 expression, respectively.

  268. 268.

    Ihara, S. et al. Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis. Cancer Res. 72, 2990–2999 (2012).

  269. 269.

    D’Incecco, A. et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br. J. Cancer 112, 95–102 (2015).

  270. 270.

    Lastwika, K. J. et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res. 76, 227–238 (2016). This study provides mechanistic insights into how activation of the AKT–mTOR pathway upregulates PDL1.

  271. 271.

    Best, S. A. et al. Synergy between the KEAP1/NRF2 and PI3K pathways drives non-small-cell lung cancer with an altered immune microenvironment. Cell Metab. 27, 935–943 (2018). References 264 and 271 demonstrate the contribution of oncogene cooperativity in mediating immune evasion in lung cancer.

  272. 272.

    Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820–827 (2005). This is the first study to demonstrate that tumour-induced bone marrow-derived progenitor cells generate a pre-metastatic niche that supports colonization of metastatic cells.

  273. 273.

    Hiratsuka, S. et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol. 10, 1349–1355 (2008).

  274. 274.

    Caetano, M. S. et al. IL6 blockade reprograms the lung tumor microenvironment to limit the development and progression of K-ras-mutant lung cancer. Cancer Res. 76, 3189–3199 (2016).

  275. 275.

    Abulaiti, A. et al. Interaction between non-small-cell lung cancer cells and fibroblasts via enhancement of TGF-β signaling by IL-6. Lung Cancer 82, 204–213 (2013).

  276. 276.

    Gao, S. P. et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 117, 3846–3856 (2007).

  277. 277.

    Yao, Z. et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc. Natl Acad. Sci. USA 107, 15535–15540 (2010).

  278. 278.

    Serresi, M. et al. Polycomb repressive complex 2 is a barrier to KRAS-driven inflammation and epithelial-mesenchymal transition in non-small-cell lung cancer. Cancer Cell 29, 17–31 (2016).

  279. 279.

    Goldstraw, P. et al. Non-small-cell lung cancer. Lancet 378, 1727–1740 (2011).

  280. 280.

    Hasegawa, Y. et al. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 91, 964–971 (2001).

  281. 281.

    Wang, W. et al. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin. Cancer Res. 15, 6630–6638 (2009).

  282. 282.

    Owusu, B. Y. et al. Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation. Oncotarget 8, 63014–63025 (2017).

  283. 283.

    Yano, S. et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J. Thorac Oncol. 6, 2011–2017 (2011).

  284. 284.

    Xia, Y. et al. Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat. Cell Biol. 14, 257–265 (2012).

  285. 285.

    Butler, J. M., Kobayashi, H. & Rafii, S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat. Rev. Cancer 10, 138–146 (2010).

  286. 286.

    Labelle, M., Begum, S. & Hynes, R. O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20, 576–590 (2011).

  287. 287.

    Hoshino, A. et al. Tumour exosome integrins determine organotropic metastasis. Nature 527, 329–335 (2015). This study demonstrates organotropic metastasis by showing that tumour exosomal α6β4 and α6β1 integrins interact with specific resident cells in the lung to achieve lung tropism.

  288. 288.

    Zhang, Y., Huang, S., Gong, D., Qin, Y. & Shen, Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8 + T lymphocytes in human non-small cell lung cancer. Cell. Mol. Immunol. 7, 389–395 (2010).

  289. 289.

    Salvador, F. et al. Lysyl oxidase-like protein LOXL2 promotes lung metastasis of breast cancer. Cancer Res. 77, 5846–5859 (2017).

  290. 290.

    Fong, M. Y. et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 17, 183–194 (2015).

Download references

Acknowledgements

The authors thank B. Sleckman, G. Koretzky and J. Cubillos-Ruiz for reading the manuscript and providing insights. They also thank S. Lee for editing this manuscript and Y. Ban and R. Shaykhiev for help with figures. The authors acknowledge funding support from US National Institutes of Health (U01 CA188388), US Department of Defense and Meyer Cancer Center Pilot grants. The authors apologize for being unable to include several excellent studies owing to space limitations.

Author information

Affiliations

  1. Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA

    • Nasser K. Altorki
    • , Geoffrey J. Markowitz
    • , Dingcheng Gao
    • , Jeffrey L. Port
    • , Brendon Stiles
    • , Timothy McGraw
    •  & Vivek Mittal
  2. Neuberger Berman Foundation Lung Cancer Research Center, Weill Cornell Medicine, New York, NY, USA

    • Nasser K. Altorki
    • , Geoffrey J. Markowitz
    • , Dingcheng Gao
    • , Jeffrey L. Port
    • , Brendon Stiles
    •  & Vivek Mittal
  3. Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA

    • Nasser K. Altorki
    • , Dingcheng Gao
    • , Jeffrey L. Port
    • , Ashish Saxena
    • , Brendon Stiles
    • , Timothy McGraw
    •  & Vivek Mittal
  4. Department of Cell and Developmental Biology, Weill Cornell Medicine, New York, NY, USA

    • Dingcheng Gao
    •  & Vivek Mittal
  5. Department of Medicine, Weill Cornell Medicine, New York, NY, USA

    • Ashish Saxena
  6. Department of Biochemistry, Weill Cornell Medicine, New York, NY, USA

    • Timothy McGraw

Authors

  1. Search for Nasser K. Altorki in:

  2. Search for Geoffrey J. Markowitz in:

  3. Search for Dingcheng Gao in:

  4. Search for Jeffrey L. Port in:

  5. Search for Ashish Saxena in:

  6. Search for Brendon Stiles in:

  7. Search for Timothy McGraw in:

  8. Search for Vivek Mittal in:

Contributions

N.K.A. and V.M. researched the data for the article and contributed to the writing of the article. V.M. reviewed and edited the manuscript before submission. A.S., B.S. and J.L.P. contributed to the clinical components of the manuscript. G.J.M. researched and organized all the information on the tumour microenvironment (TME) targets and clinical trials targeting the TME. D.G. and T.M. reviewed components related to the pre-metastatic niche and the tumour-intrinsic influence on the microenvironment.

Competing interests

The authors declare no competing interests.

Corresponding author

Correspondence to Vivek Mittal.

Supplementary information

Glossary

Aromatase

An enzyme responsible for the biosynthesis of oestrogen.

Chronic obstructive pulmonary disease

(COPD). A type of obstructive lung disease that includes chronic bronchitis and emphysema and is characterized by long-term breathing problems and poor airflow.

Desmoplasia

Excessive growth of fibrous or connective tissue around an invasive tumour.

Angiocrine signalling

Signalling that involves secreted and membrane-bound inhibitory and stimulatory growth factors, trophogens, chemokines, cytokines, extracellular matrix components, exosomes and other cellular products that are supplied by tissue-specific endothelial cells to help regulate homeostatic and regenerative processes in a paracrine or juxtacrine manner.

Degranulation

The process by which a cell releases the contents of its membrane-bound vesicles, called granules.

Tertiary lymphoid structures

(TLS). Transient ectopic lymphoid organizations that may develop after birth in non-lymphoid tissues in situations of chronic inflammation and cancer.

Doublet chemotherapy

A regimen of platinum compounds including cisplatin or carboplatin used as a standard of care in the management of advanced patients with non-small-cell lung cancer.

Immunogenic cell death

A form of cell death caused by, for example, cytostatic agents and radiation therapy that induces an effective antitumour immune response through activation of dendritic cells, which increase T cell priming.

Vascular co-option

A mechanism by which tumours obtain a blood supply from pre-existing vessels without undergoing angiogenesis. This is commonly observed in highly vascularized organs including the lungs and brain.

Cytometry by time of flight

(CyTOF). A variation of flow cytometry in which antibodies are labelled with heavy metal ion tags rather than fluorochromes. Readout is by time-of-flight mass spectrometry. This allows measurement of several cellular parameters in single samples without spectral overlap.

Radiomics

High-throughput mining of quantitative image features from standard of care medical imaging that enables data to be extracted and applied within clinical decision support systems to improve diagnostic, prognostic and predictive accuracy.

Radiopharmaceutical

The combination of a radioactive molecule, a radionuclide, that permits external detection and a biologically active molecule or drug that acts as a carrier and determines localization and biodistribution.

Rapid autopsy programmes

Programmes to arrange and perform autopsies on an urgent basis after death to collect tumour samples and other tissues for research purposes and clinical assessments.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41568-018-0081-9